A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Public ClinicalTrials.gov record NCT06966700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Study identification
- NCT ID
- NCT06966700
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,400 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab tirumotecan Biological
- Pembrolizumab Biological
- Rescue Medication Drug
- Carboplatin Drug
- Paclitaxel Drug
- Doxorubicin Drug
- Epirubicin Drug
- Cyclophosphamide Drug
- Capecitabine Drug
- Olaparib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2025
- Primary completion
- Mar 22, 2033
- Completion
- Dec 28, 2034
- Last update posted
- Aug 27, 2026
2025 – 2034
United States locations
- U.S. sites
- 60
- U.S. states
- 24
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 0066) | Gilbert | Arizona | 85234 | Recruiting |
| Mayo Clinic Cancer Center ( Site 0034) | Phoenix | Arizona | 85054 | Recruiting |
| University of Arizona Cancer Center ( Site 0035) | Tucson | Arizona | 85719 | Recruiting |
| Roy and Patricia Disney Family Cancer Center ( Site 0055) | Burbank | California | 91505 | Recruiting |
| Community Cancer Institute ( Site 0100) | Clovis | California | 93611 | Recruiting |
| Providence Medical Foundation ( Site 0080) | Fullerton | California | 92835 | Recruiting |
| MemorialCare Health System - Long Beach Medical Center ( Site 9556) | Long Beach | California | 90806 | Recruiting |
| El Camino Hospital Cancer Center ( Site 0096) | Mountain View | California | 94040 | Recruiting |
| Hoag Memorial Hospital Presbyterian ( Site 0010) | Newport Beach | California | 92663 | Recruiting |
| Helios Clinical Research ( Site 0061) | Whittier | California | 90602 | Recruiting |
| Intermountain Health Cancer Center Saint Joseph ( Site 0062) | Denver | Colorado | 80218 | Recruiting |
| Rocky Mountain Cancer Centers (RMCC) ( Site 8006) | Denver | Colorado | 80220 | Recruiting |
| Intermountain Health St. Mary's Regional Hospital ( Site 0054) | Grand Junction | Colorado | 81501 | Recruiting |
| AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) | Altamonte Springs | Florida | 32701 | Recruiting |
| Florida Cancer Specialists - South ( Site 7004) | Fort Myers | Florida | 33901 | Recruiting |
| Bioresearch Partner ( Site 0072) | Hialeah | Florida | 33013 | Recruiting |
| Mayo Clinic Hospital ( Site 0013) | Jacksonville | Florida | 32224 | Recruiting |
| Florida Cancer Specialists - North ( Site 7002) | St. Petersburg | Florida | 33701 | Recruiting |
| City of Hope Cancer Center - Atlanta ( Site 0102) | Newnan | Georgia | 30265 | Recruiting |
| Fort Wayne Medical Oncology and Hematology ( Site 0084) | Fort Wayne | Indiana | 46804 | Recruiting |
| Franciscan Health ( Site 0077) | Indianapolis | Indiana | 46237 | Recruiting |
| Ochsner Clinic Foundation ( Site 0021) | New Orleans | Louisiana | 70121 | Recruiting |
| Louisiana State University Health Sciences Shreveport ( Site 0053) | Shreveport | Louisiana | 71103 | Recruiting |
| New England Cancer Specialists ( Site 0051) | Westbrook | Maine | 04092 | Recruiting |
| Mercy Medical Center - Baltimore ( Site 0015) | Baltimore | Maryland | 21202 | Recruiting |
| Saint Luke's Cancer Institute ( Site 0059) | Kansas City | Missouri | 64111 | Recruiting |
| Washington University Siteman Cancer Center ( Site 0031) | St Louis | Missouri | 63110 | Recruiting |
| Cancer Partners of Nebraska ( Site 0068) | Lincoln | Nebraska | 68516 | Recruiting |
| Optum Care Cancer Center ( Site 0050) | Las Vegas | Nevada | 89102 | Recruiting |
| Renown Regional Medical Center ( Site 0041) | Reno | Nevada | 89502 | Recruiting |
| Hackensack Univ Medical Center (HUMC) ( Site 0007) | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0076) | New Brunswick | New Jersey | 08901 | Recruiting |
| Altru Health System ( Site 0057) | Grand Forks | North Dakota | 58201 | Recruiting |
| Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027) | Cincinnati | Ohio | 45220 | Recruiting |
| Northwest Cancer Specialists (Compass Oncology) ( Site 8010) | Tigard | Oregon | 97223 | Recruiting |
| Medical University of South Carolina-Hollings Cancer Center ( Site 0016) | Charleston | South Carolina | 29425 | Recruiting |
| St Francis Cancer Center ( Site 0093) | Greenville | South Carolina | 29607 | Recruiting |
| Avera McKennan Hospital ( Site 0002) | Sioux Falls | South Dakota | 57105 | Recruiting |
| Avera Cancer Institute - Yankton ( Site 0089) | Yankton | South Dakota | 57078 | Recruiting |
| Tennessee Cancer Specialists ( Site 7001) | Knoxville | Tennessee | 37909 | Recruiting |
| SCRI Oncology Partners ( Site 7005) | Nashville | Tennessee | 37203 | Recruiting |
| Nashville General Hospital ( Site 0017) | Nashville | Tennessee | 37208 | Recruiting |
| Vanderbilt-Ingram Cancer Center ( Site 0038) | Nashville | Tennessee | 37232 | Recruiting |
| Hendrick Medical Center ( Site 0009) | Abilene | Texas | 79601 | Recruiting |
| Texas Oncology - DFW ( Site 8009) | Dallas | Texas | 75246 | Recruiting |
| Texas Oncology - Northeast Texas ( Site 8002) | Flower Mound | Texas | 75028 | Recruiting |
| JPS Oncology and Infusion Center ( Site 0083) | Fort Worth | Texas | 76104 | Recruiting |
| Kelsey-Seybold Clinic ( Site 0042) | Houston | Texas | 77025 | Recruiting |
| Kelsey-Seybold Clinic ( Site 0088) | Houston | Texas | 77025 | Recruiting |
| Oncology Consultants P.A. ( Site 0073) | Houston | Texas | 77030 | Recruiting |
| Texas Tech University Health Sciences Center ( Site 0087) | Lubbock | Texas | 79430 | Recruiting |
| Texas Oncology - San Antonio ( Site 8004) | San Antonio | Texas | 78240 | Recruiting |
| Intermountain Medical Center ( Site 0074) | Murray | Utah | 84107 | Recruiting |
| Bon Secours Cancer Institute at St. Francis ( Site 0048) | Midlothian | Virginia | 23114 | Recruiting |
| Virginia Oncology Associates (VOA) ( Site 8008) | Norfolk | Virginia | 23502 | Recruiting |
| Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005) | Roanoke | Virginia | 24014 | Recruiting |
| Fred Hutchinson Cancer Center ( Site 0069) | Seattle | Washington | 98109 | Recruiting |
| Cancer Care Northwest ( Site 0003) | Spokane | Washington | 99202 | Recruiting |
| Northwest Medical Specialties, PLLC ( Site 0067) | Tacoma | Washington | 98405 | Recruiting |
| University of Wisconsin-Madison ( Site 0024) | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 261 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06966700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06966700 live on ClinicalTrials.gov.